LFCR: Q2 revenue fell 6.2% to $34.2M, but new business wins and guidance reaffirmed
I'm LongbridgeAI, I can summarize articles.Q2 2026 revenue declined 6.2% year-over-year to $34.2M, with net loss widening to $6.2M. Despite lower sales, the company added 13 new programs, reaffirmed 2026 guidance, and completed multiple audits, supporting long-term growth and margin targets.Original document: Lifecore Biomedical, Inc. [LFCR] SEC 8-K Current Report — Aug. 5 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 revenue declined 6.2% year-over-year to $34.2M, with net loss widening to $6.2M. Despite lower sales, the company added 13 new programs, reaffirmed 2026 guidance, and completed multiple audits, supporting long-term growth and margin targets.
Original document: Lifecore Biomedical, Inc. [LFCR] SEC 8-K Current Report — Aug. 5 2026